Rini BI - Search Results

1

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.

Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, Verzoni E. Beckermann KE, et al. Among authors: rini bi. Oncologist. 2024 Mar 4;29(3):254-262. doi: 10.1093/oncolo/oyad348. Oncologist. 2024. PMID: 38262444 Free PMC article.

2

Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.

Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Atkins MB, et al. Among authors: rini bi. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s. doi: 10.1158/1078-0432.CCR-06-2231. Clin Cancer Res. 2007. PMID: 17255291 Review.

3

Immunotherapy for metastatic renal cell carcinoma.

McDermott DF, Rini BI. McDermott DF, et al. Among authors: rini bi. BJU Int. 2007 May;99(5 Pt B):1282-8. doi: 10.1111/j.1464-410X.2007.06818.x. BJU Int. 2007. PMID: 17441925 Review. No abstract available.

4

What is standard initial systemic therapy in metastatic renal cell carcinoma?

Rini BI, McDermott D, Atkins M. Rini BI, et al. Clin Genitourin Cancer. 2007 Mar;5(4):256-63. doi: 10.3816/cgc.2007.n.001. Clin Genitourin Cancer. 2007. PMID: 17553205 Review.

5

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B. Choueiri TK, et al. Among authors: rini bi. J Clin Oncol. 2008 Jan 1;26(1):127-31. doi: 10.1200/JCO.2007.13.3223. J Clin Oncol. 2008. PMID: 18165647

6

Axitinib for renal cell carcinoma.

Sonpavde G, Hutson TE, Rini BI. Sonpavde G, et al. Among authors: rini bi. Expert Opin Investig Drugs. 2008 May;17(5):741-8. doi: 10.1517/13543784.17.5.741. Expert Opin Investig Drugs. 2008. PMID: 18447599 Review.

7

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ. Rini BI, et al. J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416. J Clin Oncol. 2008. PMID: 18669461 Clinical Trial.

8

Renal cell carcinoma.

Rini BI, Campbell SC, Escudier B. Rini BI, et al. Lancet. 2009 Mar 28;373(9669):1119-32. doi: 10.1016/S0140-6736(09)60229-4. Epub 2009 Mar 5. Lancet. 2009. PMID: 19269025 Free article. Review.

9

Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.

Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG Jr, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Atkins MB, et al. Among authors: rini bi. Cancer. 2009 May 15;115(10 Suppl):2247-51. doi: 10.1002/cncr.24229. Cancer. 2009. PMID: 19402064 Free PMC article.

10

Resistance to targeted therapy in renal-cell carcinoma.

Rini BI, Atkins MB. Rini BI, et al. Lancet Oncol. 2009 Oct;10(10):992-1000. doi: 10.1016/S1470-2045(09)70240-2. Lancet Oncol. 2009. PMID: 19796751 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

417 results

Search Page